Research published in the American Journal of Gastroenterology shows that an exclusion diet combined with medical treatment can increase healing rates in patients with chronic anal fissure who have been referred for surgery.
[More]
Fissurectomy results in high levels of healing and low rates of anal incontinence, show the results of the largest ever prospective study of the technique.
[More]
ProStrakan Group plc, a subsidiary of Kyowa Hakko Kirin Co. Ltd., and an international specialty pharmaceutical company, today announces that it has received approval from the U.S. Food and Drug Administration (FDA) for Rectiv™ (nitroglycerin) Ointment 0.4 % for the treatment of moderate to severe pain associated with chronic anal fissures.
[More]
While botulinum toxin A, or BTXA, is widely known for its use in dermatology and aesthetic medicine, a review article in the Journal of Cosmetic Dermatology explores the drug’s other successful applications.
[More]
Cellegy Pharmaceuticals has announced receipt of a communication from the U.S. Food and Drug Administration in the form of a Not Approvable Letter for its product Cellegesic(TM) (nitroglycerin ointment).
[More]